• Jean-Michel Hannoun-Levi, Alexandra Resch, Jocelyn Gal, Daniela Kauer-Dorner, Vratislav Strnad, Peter Niehoff, Kristina Loessl, Gyoergy Kovács, Erick Van Limbergen, Csaba Polgár, and GEC-ESTRO Breast Cancer Working Group.
• Department of Radiation Oncology, Antoine Lacassagne Cancer Center, University of Nice-Sophia, France. Electronic address: jean-michel.hannoun-levi@nice.unicancer.fr.
• Radiother Oncol. 2013 Aug 1; 108 (2): 226-31.

PurposeTo analyse the clinical outcome after salvage lumpectomy and multi-catheter brachytherapy (MCB) for ipsilateral breast tumour recurrence (IBTR).Material And MethodsBetween 09/00 and 09/10, 217 patients presenting an IBTR underwent lumpectomy and MCB (low, pulsed, or high-dose rate). Survival rates without second local recurrence (2nd LR), distant metastasis (DM), and overall survival (OS) were analysed as well as late effects and cosmetic results. Univariate and multivariate analyses (MVA) based on IBTR data were performed to find prognostic factors for 2nd LR, DM, and OS.ResultsMedian follow-up after the IBTR was 3.9 years [range: 1.1-10.3]. Five and 10-year actuarial 2nd LR rates were 5.6% [range: 1.5-9.5] and 7.2% [range: 2.1-12.1], respectively. Five and 10-year actuarial DM rates were 9.6% [range: 5.7-15.2] and 19.1% [range: 7.8-28.3], respectively. Five and 10-year actuarial OS rates were 88.7% [range: 83.1-94.8] and 76.4% [range: 66.9-87.3], respectively. In MVA, histological grade was prognostic factor for 2nd LR (p=0.008) and OS (p=0.02); while tumour size was prognostic factor for DM (p=0.03). G3-4 complication rate was 11%. Excellent/good cosmetic result was achieved in 85%.ConclusionThis study suggests that in case of IBTR, lumpectomy plus MCB is feasible and effective in preventing 2nd LR with an OS rate at least equivalent to those achieved with salvage mastectomy.Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

54 keywords...

hide…